Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best strong buy healthcare stocks to invest in. Revolution Medicines, Inc. (NASDAQ:RVMD) was initiated with an Outperform rating and a $140 price target by Evercore ISI on February 25. The firm set a $140 price target on the stock, stating that with the expected launch of daraxonrasib, the company is “poised for a potential breakthrough in oncology”. With strategic distractions fading, Evercore sees “a promising entry point” ahead of key Phase 3 data in pancreatic cancer expected in the first half of 2026.
The rating update came the same day Revolution Medicines, Inc. (NASDAQ:RVMD) announced its fiscal Q4 and full year 2025 results, reporting cash, cash equivalents, and marketable securities of $2.0 billion as of December 31, 2025.
Research and development expenses for the quarter were $294.9 million, compared to $188.1 million for the previous year period. The company attributed the increase to a rise in clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib, along with an increase in personnel-related expenses and stock-based compensation expense related to additional headcount.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.
While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
